Aster DM Quality Care Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Aster DM Quality Care Ltd filed with BSE on 12 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Aster DM Quality Care reported its first combined proforma results after the merger of Aster DM Healthcare and Quality Care, with revenue up 20% year-on-year to Rs 2,597 crores and EBITDA up 30% to Rs 576 crores in Q1 FY27. Management attributed growth to higher patient volumes, improved case mix, occupancy expansion, and strong growth in medical value travel revenue. Aster DM Healthcare standalone revenue grew 22% to Rs 1,311 crore while Quality Care revenue grew 19% to Rs 1,287 crore, both with margin expansion.
Numbers mentioned
Revenue from operations (combined proforma): INR 2,597 crores (Q1 FY27)
p. 4
“Revenue from operations increased 20% year-on-year to INR 2,597 crores.”
Varun Khanna, page 4 of the filed PDF · View the filing
EBITDA (combined proforma): INR 576 crores (Q1 FY27)
p. 5
“EBITDA grew 30% YoY to INR 576 crores.”
Varun Khanna, page 5 of the filed PDF · View the filing
EBITDA Margin (combined proforma): 22.2% (Q1 FY27)
p. 5
“The EBITDA Margin expanded by 170 bps YoY to 22.2%.”
Varun Khanna, page 5 of the filed PDF · View the filing
Patients treated: over 2 million, up 13% YoY (Q1 FY27)
p. 5
“We treated over 2 million patients in Q1, up 13% YoY, with blended occupancy expanding 510 bps YoY to 64%.”
Varun Khanna, page 5 of the filed PDF · View the filing
MVT revenue growth: 62% YoY (Q1 FY27)
p. 5
“This was supported by 62% YoY growth in Medical Value Travel (MVT) revenue on account of addition of new geographies.”
Varun Khanna, page 5 of the filed PDF · View the filing
Aster DM Healthcare revenue: Rs. 1,311 Cr (Q1 FY27)
p. 6
“I am delighted to share that Aster DM delivered a strong start to FY27, with revenue increasing 22% year-on-year to Rs. 1,311 Cr, compared to Rs. 1,078 Cr in Q1 FY26.”
Sunil Kumar, page 6 of the filed PDF · View the filing
Aster DM Healthcare Operating EBITDA: Rs. 277 Cr (Q1 FY27)
p. 6
“Operating EBITDA increased 29% to Rs. 277 Cr, while the operating EBITDA margin expanded by 117 basis points to 21.1%.”
Sunil Kumar, page 6 of the filed PDF · View the filing
Aster DM Healthcare Normalised PAT: approximately Rs. 125 Cr (Q1 FY27)
p. 6
“Normalised PAT, excluding exceptional costs, increased 39% year-on-year to approximately Rs. 125 Cr, compared with Rs. 90 Cr in the corresponding quarter last year.”
Sunil Kumar, page 6 of the filed PDF · View the filing
Exceptional expense (merger costs): INR 114 Cr (Q1 FY27)
p. 6
“The exceptional expense of INR 114 Cr pertains entirely to costs incurred”
Sunil Kumar, page 6 of the filed PDF · View the filing
Return on Capital Employed: 22.6% (Q1 FY27)
p. 7
“Return on Capital Employed improved by approximately 190 basis points to 22.6%, compared with 20.7% in the corresponding period last year.”
Sunil Kumar, page 7 of the filed PDF · View the filing
Quality Care revenue: INR 1,287 Cr (Q1 FY27)
p. 7
“Quality Care delivered a standout quarter, with revenue growing 19% YoY to INR 1,287 Cr and Operating EBITDA surging 32% YoY to 299 Cr, and margin expansion of 216 bps reaching 23.2% in Q1FY27.”
Sunil Kumar, page 7 of the filed PDF · View the filing
Quality Care occupancy: 65.4% (Q1 FY27)
p. 7
“This strong performance was driven by a 656 bps jump in occupancy to 65.4%, deeper clinical mix, robust growth in robotic, transplants and joint replacement along with better payor mix which boosted the ARPP IP, reaching ~INR 144k in Q1FY27.”
Sunil Kumar, page 7 of the filed PDF · View the filing
Combined net debt: INR 1162 Crore (as on 30 June 2026)
p. 7
“At the combined level there is a net debt of INR 1162 Crore as on 30 June 2026.”
Sunil Kumar, page 7 of the filed PDF · View the filing
Mature Units revenue growth: 19% YoY (Q1 FY27)
p. 5
“Growth across our unit mix remained robust with Mature Units contributing 73% to the total revenue recorded 19% YoY revenue growth, driven by steady bed throughput, higher ARPP IP driven by improved case mix, better Payor mix and higher MVT contribution.”
Varun Khanna, page 5 of the filed PDF · View the filing
Emerging Segment revenue growth: 63% YoY (Q1 FY27)
p. 5
“Emerging Segment which is the newer hospitals registered the highest growth trajectory at 63% YoY revenue growth, propelled by fast-paced patient volume ramp-ups at newly commissioned facilities.”
Varun Khanna, page 5 of the filed PDF · View the filing
Robotics volume growth: ~80% YoY (Q1 FY27)
p. 6
“What will interest you is that our Robotics Volumes witnessed ~80% growth over the same period last year with Joint replacements increasing by 39% over last year and transplants up by 19% YoY”
Varun Khanna, page 6 of the filed PDF · View the filing
Planned bed additions: over 4,170 beds (next 3 to 4 years)
p. 6
“We have a clear roadmap to add over 4,170 beds over the next 3 to 4 years, taking our total capacity over 15,000 beds.”
Varun Khanna, page 6 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA margin — 24%-25% · two to three years post-merger
stated firmly by Sunil Kumar M R
p. 9
“You can see that the quarter has been a great start, we still hold on to our broader guidance of two to three years post-merger, we are on our way to hit that number of 24%-25%.”
Sunil Kumar M R, page 9 of the filed PDF · View the filing
EBITDA margin — 24%, 25% · between 2028 to 2029
stated conditionally by Sunil Kumar M R
p. 18
“Somewhere between 2028 to 2029, I think we should reach our targets.”
Sunil Kumar M R, page 18 of the filed PDF · View the filing
Merger synergy benefit to EBITDA — 10%-15% of FY24 pro forma EBITDA · this financial year onwards
stated firmly by Varun Khanna
p. 9
“We had said that about a year back that we hope to bring in 10%-15% incremental EBITDA on account of synergies, and we still stick to that.”
Varun Khanna, page 9 of the filed PDF · View the filing
Merger synergy benefit to EBITDA — 10%-15% of FY24 EBITDA (INR 150-200 crore)
stated firmly by Varun Khanna
p. 19
“as of now, the commitment to drive is 10%-15% of the FY24 EBITDA, and that itself is a very good quantum.”
Varun Khanna, page 19 of the filed PDF · View the filing
MVT revenue growth — in excess of 50%
stated as an aspiration by Varun Khanna
p. 18
“We will continue to grow in excess of 50%, is where we see it.”
Varun Khanna, page 18 of the filed PDF · View the filing
MVT share of total revenue — double digit · over the next couple of years
stated as an aspiration by Alisha Moopen
p. 11
“I think trying to get it to double digit is sort of a goal that we will have over the next couple of years”
Alisha Moopen, page 11 of the filed PDF · View the filing
Organic volume and ARPP growth — 5%-6% volume growth and 7%-8% ARPP growth · in two to three years
stated conditionally by Sunil Kumar M R
p. 15
“if I were to generate a 24%-25% of EBITDA margin in two to three year’s time, we should be able to generate at organic level 5%-6% volume growth and maybe 7%-8% of the ARPP growth.”
Sunil Kumar M R, page 15 of the filed PDF · View the filing
Aster Capital (Trivandrum) hospital commissioning — H2 FY2027, most probably January
stated firmly by Sunil Kumar M R
p. 16
“I think we have said H2 FY 2027, and most probably somewhere in the month of January, we should be able to operationalize the Trivandrum hospital.”
Sunil Kumar M R, page 16 of the filed PDF · View the filing
Hyderabad hospital commissioning — April 2027
stated conditionally by Sunil Kumar M R
p. 16
“If that goes well, I think we should be able to operationalize sometime in the April 2027.”
Sunil Kumar M R, page 16 of the filed PDF · View the filing
Sarjapur hospital Phase I commissioning — second half of FY28
stated conditionally by Sunil Kumar M R
p. 17
“Going well, I think at least the phase I, which is the first A block, we should be able to operationalize in the second half of FY28.”
Sunil Kumar M R, page 17 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management declined to give a quarterly/yearly guidance and reiterated the broader two-to-three-year target of 24%-25%.
Answered by Sunil Kumar M R
Asked by Tausif Shaikh: What EBITDA margin should be expected for FY27 after the strong start to the year?
p. 9
“Tausif, I think we have previously called out that we will not give a guidance on quarter on quarter or yearly basis.”
Sunil Kumar M R, page 9 of the filed PDF · View the filing
Varun said merger synergies have not yet played out since integration only started, and reiterated the prior guidance of 10-15% incremental EBITDA from synergies.
Answered by Varun Khanna
Asked by Damyanti Kerai: What further cost efficiency opportunities exist beyond what's already been captured, and how will merger synergies play out?
p. 9
“I'm also not saying it's going to play out this quarter, but you will start to see significant results on our synergies this financial year onwards.”
Varun Khanna, page 9 of the filed PDF · View the filing
Sunil attributed Karnataka's earlier slowdown to doctor attrition, now reversed through new hires, and described Kerala's recovery driven by volume growth and the Kasaragod facility breaking even quickly.
Answered by Sunil Kumar M R
Asked by Siddharth: What drove slower growth in Maharashtra and Karnataka, and how is Kerala's recovery progressing?
p. 13
“I would like to also call out very clearly, only in Q1 I'm talking about, we have been acquiring clinical talent over the last second of H2 of FY26.”
Sunil Kumar M R, page 13 of the filed PDF · View the filing
Sunil said growth could moderate temporarily due to competition but expected double-digit to mid-teens growth to be sustainable.
Answered by Sunil Kumar M R
Asked by Bino Pathiparampil: Is the strong growth rate in markets like Bangalore sustainable for the rest of the year?
p. 15
“I think we are talking about anywhere double-digit growth. Even the lower to mid-teen growth. I think that is something which is sustainable.”
Sunil Kumar M R, page 15 of the filed PDF · View the filing
Varun said the commitment remains 10-15% of FY24 EBITDA though there is always upside as growth continues.
Answered by Varun Khanna
Asked by Mohammed Patel: Is there upside potential to the stated 10-15% synergy target?
p. 19
“No, you know, that is something which we are committed. always there is upside when you do the growth.”
Varun Khanna, page 19 of the filed PDF · View the filing
Risks flagged
Neighborhood competition can cause temporary softness in growth in certain markets
p. 15
“whenever there is a neighborhood competition coming in, you will have some softness in the growth for one or two quarter, slowly it'll come back.”
Sunil Kumar M R, page 15 of the filed PDF · View the filing
Doctor attrition previously slowed growth in Karnataka
p. 13
“FY26, I think the first two or three quarters, we had a little bit of attrition in some of the doctors, and we went into even a single digit growth.”
Sunil Kumar M R, page 13 of the filed PDF · View the filing
Merger integration and synergy realization have not yet fully materialized
p. 9
“For merged entity, synergies haven't played out. As I told you, we've not started working on the merged entity synergies previously.”
Varun Khanna, page 9 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.